SEC Filing Summary: Intrexon Corporation (Precigen, Inc.)
Business Context and Reporting Period
This Form 8-K was filed by Intrexon Corporation on January 7, 2019. The report concerns Precigen, Inc., a wholly-owned subsidiary of Intrexon. The filing serves as a Regulation FD disclosure regarding a presentation scheduled for the 2019 J.P. Morgan Healthcare Conference.
Key Financial Metrics
The filing text does not provide specific financial values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to disclose the existence of a presentation rather than a financial report containing quantitative data.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document solely announces the delivery of a presentation by Precigen, Inc. at an external conference.
Guidance, Outlook, and Risks
The filing incorporates by reference a presentation (Exhibit 99.1) intended for the 2019 J.P. Morgan Healthcare Conference. However, the text of the 8-K itself does not contain the content of the presentation, specific guidance, management commentary, or risk factors. The filing explicitly states that the information in Item 7.01 and the exhibit will not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the content of the presentation attached as Exhibit 99.1 for specific business updates or guidance.
- Confirm the relationship between Intrexon Corporation and Precigen, Inc. as a wholly-owned subsidiary.
- Note that this filing does not constitute a formal financial report or filed disclosure under Section 18 of the Exchange Act.